Multi-target design strategies for the improved treatment of Alzheimer's disease
P Zhang, S Xu, Z Zhu, J Xu - European journal of medicinal chemistry, 2019 - Elsevier
Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and
poses a substantial burden on human health, economy, and society throughout the world …
poses a substantial burden on human health, economy, and society throughout the world …
Multitarget therapeutic strategies for Alzheimer's disease
Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases
have multifaceted nature because of the different factors contributing to their progression …
have multifaceted nature because of the different factors contributing to their progression …
A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease
Abstract Alzheimer's disease (AD), the most common form of dementia, is a multifactorial
neurodegenerative disease. The target enzymes inhibition including cholinesterase, beta …
neurodegenerative disease. The target enzymes inhibition including cholinesterase, beta …
[HTML][HTML] Novel lactopeptides in fermented dairy products improve memory function and cognitive decline
Y Ano, T Ayabe, T Kutsukake, R Ohya, Y Takaichi… - Neurobiology of …, 2018 - Elsevier
Alongside the rapid growth in aging populations, prevention of age-related memory decline
and dementia has become a high priority. Several epidemiological and clinical studies have …
and dementia has become a high priority. Several epidemiological and clinical studies have …
Chromanone-A prerogative therapeutic scaffold: an overview
S Kamboj, R Singh - Arabian journal for science and engineering, 2022 - Springer
Chromanone or Chroman-4-one is the most important and interesting heterobicyclic
compound and acts as a building block in medicinal chemistry for isolation, designing and …
compound and acts as a building block in medicinal chemistry for isolation, designing and …
Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease–a patent review (2016–present)
M Bortolami, D Rocco, A Messore… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction–AD, the most common form of dementia, has a multifactorial etiology, and the
current therapy (AChEIs and memantine) is unable to interrupt its progress and fatal …
current therapy (AChEIs and memantine) is unable to interrupt its progress and fatal …
Multitarget tacrine hybrids with neuroprotective properties to confront Alzheimer's disease
K Spilovska, J Korabecny… - Current Topics in …, 2017 - ingentaconnect.com
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Several hallmarks
such as β-amyloid (Aβ) aggregation underlying amyloid plaque formation, Τ …
such as β-amyloid (Aβ) aggregation underlying amyloid plaque formation, Τ …
Perspectives for new and more efficient multifunctional ligands for Alzheimer′ s disease therapy
Despite tremendous research efforts at every level, globally, there is still a lack of effective
drugs for the treatment of Alzheimer′ s disease (AD). The biochemical mechanisms of this …
drugs for the treatment of Alzheimer′ s disease (AD). The biochemical mechanisms of this …
Recent advances in virtual screening for cholinesterase inhibitors
Alzheimer's disease (AD) is a significant health crisis, and current treatments provide only
limited benefits to cognition at the cost of serious side effects. Recently, virtual screening …
limited benefits to cognition at the cost of serious side effects. Recently, virtual screening …
Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds
JP Lee, MG Kang, JY Lee, JM Oh, SC Baek… - Bioorganic …, 2019 - Elsevier
Six hundred forty natural compounds were tested for acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE) inhibitory activities. Of those, sargachromanol I (SCI) and G …
butyrylcholinesterase (BChE) inhibitory activities. Of those, sargachromanol I (SCI) and G …